A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rana R. McKay, Pamela J. Atherton, Karla V. Ballman, Heather Jacene, Ronald C. Chen, Atish Dipankar Choudhury, Joshua Michael Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Alan Tan, Stephanie A. Berg, Himisha Beltran, Michael J. Morris, Bradley Alexander McGregor, Tian Zhang, Matthew D. Galsky, Jonathan E. Rosenberg, Daniel J. George, Toni K. Choueiri
Institutions: Moores Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, University of Kansas Medical Center, University of Wisconsin–Madison, The University of Texas Southwestern Medical Center, IHA Hematology Oncology Consultants, University of Maryland Medical Center, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Harold C. Simmons Comprehensive Cancer Center, Tisch Cancer Institute, Duke University, Duke Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162501874